CYTR CytRx Corporation

+0  (3%)
Previous Close 0.83
Open 0.90
Price To book 4.26
Market Cap 100.31M
Shares 117,322,000
Volume 22,849,229
Short Ratio 7.79
Av. Daily Volume 2,836,580

SEC filingsSee all SEC filings

  1. EFFECT - Notice of Effectiveness 17777082
  2. 8-K - Current report 17769449
  3. S-3 - Registration statement under Securities Act of 1933 17747209
  4. 424B3 - Prospectus (Rule 424(b)(3)) 17734429
  5. 424B3 - Prospectus (Rule 424(b)(3)) 17734387

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 data presented October 10 2016.
Advanced sarcomas - cancer
Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma. Rolling NDA to be filed 4Q 2017.
Aldoxorubicin with doxorubicin
Soft tissue sarcomas refractory cancer
Phase 2 completed.
Cancer - AIDS-related Kaposi’s sarcoma
Phase 2 trial completed.
Cancer - unresectable glioblastoma
Phase 2b data due 2Q 2017.
Relapsed/refractory small cell lung cancer

Latest News

  1. CytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)
  2. CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up
  3. ETFs with exposure to CytRx Corp. : April 20, 2017
  4. Blog Coverage CytRx Announces FDA's Approval for New Drug Application
  5. CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
  6. For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1
  7. ETFs with exposure to CytRx Corp. : March 27, 2017
  8. CytRx Corp. :CYTR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  9. CytRx Reports 2016 Financial Results
  10. The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
  11. CytRx to Present at the 29th Annual ROTH Conference
  12. CytRx to Present at the 19th Annual BIO CEO & Investor Conference
  13. CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue Sarcomas
  14. Is the Options Market Predicting a Spike in CytRx Corp (CYTR) Stock?
  15. CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer
  16. How CytRx Corporation (CYTR) Stacks Up Against Its Peers
  17. CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common Stock
  18. Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board of Directors
  19. CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA